Literature DB >> 11931728

Human Immunodeficiency Virus (HIV) in Children.

Claudia A. Chiriboga1.   

Abstract

Recent advances in antiretroviral treatment have changed the landscape of pediatric HIV--not only has perinatal treatment markedly diminished HIV transmission rates, but highly active antiretroviral treatments (HAART) have, with few exceptions, transformed HIV into a chronic nonfatal disorder. Antiretroviral therapies are complex and fraught with potential for side effects. The neurologist involved with HIV-infected children should have a firm grasp on the different therapeutic agents used among infected children, especially as regards drug metabolism and indications for treatment.

Entities:  

Year:  2002        PMID： 11931728     DOI： 10.1007/s11940-002-0038-9

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN： 1092-8480            Impact factor:   3.972


  25 in total

1.  Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.

Authors:  V A Eagling; D J Back; M G Barry
Journal:  Br J Clin Pharmacol       Date:  1997-08       Impact factor: 4.335

2.  Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.

Authors:  S A Nachman; K Stanley; R Yogev; S Pelton; A Wiznia; S Lee; L Mofenson; S Fiscus; M Rathore; E Jimenez; W Borkowsky; J Pitt; M E Smith; B Wells; K McIntosh
Journal:  JAMA       Date:  2000-01-26       Impact factor: 56.272

Review 3.  HIV-1 encephalopathy in children.

Authors:  H A Gelbard; L G Epstein
Journal:  Curr Opin Pediatr       Date:  1995-12       Impact factor: 2.856

4.  Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1998-04-24

5.  Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1.

Authors:  S L Gortmaker; M Hughes; J Cervia; M Brady; G M Johnson; G R Seage; L Y Song; W M Dankner; J M Oleske
Journal:  N Engl J Med       Date:  2001-11-22       Impact factor: 91.245

Review 6.  AIDS and pediatric neurology.

Authors:  A L Belman
Journal:  Neurol Clin       Date:  1990-08       Impact factor: 3.806

7.  Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team.

Authors:  A Wiznia; K Stanley; P Krogstad; G Johnson; S Lee; J McNamara; J Moye; J B Jackson; H Mendez; R Aguayo; A Dieudonne; A Kovacs; M Bamji; E Abrams; S Rana; J Sever; S Nachman
Journal:  AIDS Res Hum Retroviruses       Date:  2000-08-10       Impact factor: 2.205

8.  Adherence to medication regimens among children with human immunodeficiency virus infection.

Authors:  C Reddington; J Cohen; A Baldillo; M Toye; D Smith; C Kneut; A Demaria; J Bertolli; H W Hsu
Journal:  Pediatr Infect Dis J       Date:  2000-12       Impact factor: 2.129

Review 9.  Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor.

Authors:  H B Fung; H L Kirschenbaum; R Hameed
Journal:  Clin Ther       Date:  2000-05       Impact factor: 3.393

10.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  E M Connor; R S Sperling; R Gelber; P Kiselev; G Scott; M J O'Sullivan; R VanDyke; M Bey; W Shearer; R L Jacobson
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.